SPI1 [The Human Chemical-Genetic Interaction Map Project]

This page is read only. You can view the source, but not change it. Ask your administrator if you think this is wrong.
======= SPI1 =======


== Gene Information ==
  * **<color #00a2e8>Official Symbol</color>**: SPI1
  * **<color #00a2e8>Official Name</color>**: Spi-1 proto-oncogene
  * **<color #00a2e8>Aliases and Previous Symbols</color>**: N/A
  * **<color #00a2e8>Entrez ID</color>**: [[https://www.ncbi.nlm.nih.gov/gene/?term=6688|6688]]
  * **<color #00a2e8>UniProt</color>**: [[https://www.uniprot.org/uniprot/P17947|P17947]]
  * **<color #00a2e8>Interactions</color>**: [[https://thebiogrid.org/search.php?search=SPI1&organism=9606|BioGRID]]
  * **<color #00a2e8>PubMed articles</color>**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20SPI1|Open PubMed]]
  * **<color #00a2e8>OMIM</color>**: [[https://omim.org/entry/165170|Open OMIM]]

== Function Summary ==
  * **<color #00a2e8>Entrez Summary</color>**: N/A
  * **<color #00a2e8>UniProt Summary</color>**:  Binds to the PU-box, a purine-rich DNA sequence (5'- GAGGAA-3') that can act as a lymphoid-specific enhancer. This protein is a transcriptional activator that may be specifically involved in the differentiation or activation of macrophages or B- cells. Also binds RNA and may modulate pre-mRNA splicing (By similarity). {ECO:0000250}.

<button type='primary' size='sm' modal='Pfam_Domains'>Pfam Domains</button>
<button type='primary' size='sm' modal='GO_terms'>GO Terms</button>


<modal id='Pfam_Domains' size='lg' title='Pfam Domains'>
|Ets|
</modal>

<modal id='GO_terms' size='lg' title='GO Terms'>
|hypermethylation of CpG island|
|DNA hypermethylation|
|apoptotic process involved in blood vessel morphogenesis|
|NFAT protein binding|
|negative regulation of histone H4 acetylation|
|negative regulation of MHC class II biosynthetic process|
|pri-miRNA transcription by RNA polymerase II|
|anatomical structure regression|
|lymphoid progenitor cell differentiation|
|regulation of histone H4 acetylation|
|regulation of MHC class II biosynthetic process|
|cellular response to ethanol|
|negative regulation of histone acetylation|
|apoptotic process involved in morphogenesis|
|interleukin-6-mediated signaling pathway|
|myeloid dendritic cell differentiation|
|negative regulation of peptidyl-lysine acetylation|
|granulocyte differentiation|
|negative regulation of protein acetylation|
|myeloid dendritic cell activation|
|macrophage differentiation|
|regulation of DNA methylation|
|apoptotic process involved in development|
|positive regulation of pri-miRNA transcription by RNA polymerase II|
|dendritic cell differentiation|
|cellular response to interleukin-6|
|response to interleukin-6|
|negative regulation of histone modification|
|regulation of pri-miRNA transcription by RNA polymerase II|
|regulation of erythrocyte differentiation|
|histone H3 acetylation|
|regulation of histone acetylation|
|negative regulation of chromatin organization|
|regulation of peptidyl-lysine acetylation|
|RNA polymerase II transcription factor binding|
|somatic stem cell population maintenance|
|regulation of protein acetylation|
|erythrocyte differentiation|
|negative regulation of gene expression, epigenetic|
|cellular response to alcohol|
|hematopoietic progenitor cell differentiation|
|erythrocyte homeostasis|
|RNA polymerase II distal enhancer sequence-specific DNA binding|
|myeloid cell homeostasis|
|myeloid leukocyte differentiation|
|histone acetylation|
|cellular response to antibiotic|
|internal peptidyl-lysine acetylation|
|peptidyl-lysine acetylation|
|internal protein amino acid acetylation|
|response to ethanol|
|negative regulation of chromosome organization|
|stem cell population maintenance|
|maintenance of cell number|
|protein acetylation|
|regulation of histone modification|
|protein acylation|
|regulation of chromatin organization|
|homeostasis of number of cells|
|transcription factor complex|
|cellular response to toxic substance|
|myeloid cell differentiation|
|regulation of myeloid cell differentiation|
|response to alcohol|
|regulation of gene expression, epigenetic|
|lymphocyte differentiation|
|nuclear chromatin|
|DNA-binding transcription repressor activity, RNA polymerase II-specific|
|response to antibiotic|
|peptidyl-lysine modification|
|leukocyte differentiation|
|transcription factor binding|
|regulation of chromosome organization|
|regulation of DNA metabolic process|
|histone modification|
|negative regulation of organelle organization|
|covalent chromatin modification|
|lymphocyte activation|
|cellular response to drug|
|blood vessel morphogenesis|
|DNA-binding transcription activator activity, RNA polymerase II-specific|
|regulation of hemopoiesis|
|transcription by RNA polymerase II|
|blood vessel development|
|RNA polymerase II proximal promoter sequence-specific DNA binding|
|response to toxic substance|
|vasculature development|
|cardiovascular system development|
|hemopoiesis|
|myeloid leukocyte activation|
|negative regulation of protein modification process|
|hematopoietic or lymphoid organ development|
|transcription, DNA-templated|
|nucleic acid-templated transcription|
|immune system development|
|RNA biosynthetic process|
|tube morphogenesis|
|cytokine-mediated signaling pathway|
|DNA-binding transcription factor activity|
|chromatin organization|
|negative regulation of cellular component organization|
|tube development|
|negative regulation of transcription by RNA polymerase II|
|circulatory system development|
|peptidyl-amino acid modification|
|apoptotic process|
|leukocyte activation|
|cellular response to cytokine stimulus|
|response to drug|
|negative regulation of cellular protein metabolic process|
|programmed cell death|
|cellular response to oxygen-containing compound|
|chromosome organization|
|cell activation|
|cell death|
|nucleobase-containing compound biosynthetic process|
|response to cytokine|
|negative regulation of protein metabolic process|
|heterocycle biosynthetic process|
|aromatic compound biosynthetic process|
|negative regulation of transcription, DNA-templated|
|positive regulation of transcription by RNA polymerase II|
|negative regulation of nucleic acid-templated transcription|
|negative regulation of RNA biosynthetic process|
|regulation of organelle organization|
|organic cyclic compound biosynthetic process|
|negative regulation of RNA metabolic process|
|negative regulation of cellular macromolecule biosynthetic process|
|RNA binding|
|negative regulation of nucleobase-containing compound metabolic process|
|negative regulation of macromolecule biosynthetic process|
|negative regulation of cellular biosynthetic process|
|positive regulation of transcription, DNA-templated|
|negative regulation of biosynthetic process|
|response to oxygen-containing compound|
|DNA-binding transcription factor activity, RNA polymerase II-specific|
|cellular nitrogen compound biosynthetic process|
|positive regulation of nucleic acid-templated transcription|
|positive regulation of RNA biosynthetic process|
|homeostatic process|
|regulation of immune system process|
|RNA metabolic process|
|cellular macromolecule biosynthetic process|
|negative regulation of gene expression|
|positive regulation of RNA metabolic process|
|macromolecule biosynthetic process|
|regulation of cell differentiation|
|regulation of protein modification process|
|positive regulation of nucleobase-containing compound metabolic process|
|positive regulation of macromolecule biosynthetic process|
|positive regulation of cellular biosynthetic process|
|positive regulation of gene expression|
|gene expression|
|positive regulation of biosynthetic process|
</modal>
\\

 === CRISPR Data ===
<button type='primary' size='small' modal='Compound_Hit'>Compound Hit</button>
<button type='primary' size='small' modal='Most_Correlated_Genes'>Most Correlated Genes in Chemogenomics</button>
<button type='primary' size='small' modal='Essential_Avana'>Tissues where Essential in the Avana Dataset (DepMap 20Q1)</button>

<modal id='Compound_Hit' size='lg' title='Compound Hit'>
^Screen^Score^
|[[:results:exp488|Hippuristanol 0.12μM R08 exp488]]|-3.01|
|[[:results:exp120|Dimethyl-Sulfoxide 1pc R03 exp120]]|-2.89|
|[[:results:exp28|Pimelic-diphenylamide-106 5μM R00 exp28]]|-2.58|
|[[:results:exp489|Hippuristanol 0.12μM R08 exp489 no dilution day6]]|-2.56|
|[[:results:exp535|Trimetrexate 0.03μM R08 exp535]]|-2.56|
|[[:results:exp17|DABN 20μM R00 exp17]]|-2.36|
|[[:results:exp531|THZ1 0.06μM R08 exp531]]|-2.34|
|[[:results:exp440|Aphidicolin 0.4μM R08 exp440]]|-2.28|
|[[:results:exp502|Milciclib 2μM R08 exp502]]|-2.18|
|[[:results:exp94|Nocodazole 0.1μM R03 exp94]]|-2.14|
|[[:results:exp453|B02 10μM R08 exp453]]|-2.08|
|[[:results:exp226|Cerivastatin 0.15μM R05 exp226]]|-2.05|
|[[:results:exp526|Sulforaphane 9μM R08 exp526 no dilution day6]]|-2.05|
|[[:results:exp524|Staurosporine 0.02μM R08 exp524]]|-1.98|
|[[:results:exp46|HMS-I1 1μM R01 exp46]]|-1.95|
|[[:results:exp525|Sulforaphane 9μM R08 exp525]]|-1.9|
|[[:results:exp259|6-Thio-2-deoxyguanosine 2μM R06 exp259]]|-1.82|
|[[:results:exp480|ETC-159 50μM R08 exp480]]|-1.81|
|[[:results:exp60|Vinblastine 0.002μM R01 exp60]]|-1.77|
|[[:results:exp264|Arsenate 40μM R06 exp264]]|-1.75|
|[[:results:exp391|Pomalidomide 20μM R07 exp391]]|1.76|
|[[:results:exp318|ABT-702 5μM R07 exp318]]|1.83|
|[[:results:exp47|Lapatinib 5μM R01 exp47]]|1.83|
|[[:results:exp420|Tunicamycin 0.04 to 0.125μM  on day4 R07 exp420]]|1.91|
|[[:results:exp495|IWR1 50μM R08 exp495]]|2.02|
|[[:results:exp70|INK128 0.2μM R02 exp70]]|2.03|
|[[:results:exp38|Wortmannin 5μM R00 exp38]]|2.06|
|[[:results:exp84|UM0125461 0.74μM R02 exp84]]|2.07|
|[[:results:exp198|Etoposide 0.1μM R05 exp198]]|2.1|
|[[:results:exp419|Tunicamycin 0.04 to 0.075μM  on day4 R07 exp419]]|2.17|
|[[:results:exp90|WYE-354 6μM R02 exp90]]|2.29|
|[[:results:exp418|Tunicamycin 0.04μM R07 exp418]]|2.36|
|[[:results:exp326|CCT251545 20μM R07 exp326]]|2.41|
|[[:results:exp35|TRAIL 5ng/ml R00 exp35]]|2.44|
|[[:results:exp538|ZLN024 50μM R08 exp538]]|2.63|
|[[:results:exp36|TRAIL 50ng/ml R00 exp36]]|2.64|
|[[:results:exp222|Betulinic acid 10 to 15μM on day4 R05 exp222]]|3.12|
|[[:results:exp492|iCRT14 30μM R08 exp492]]|3.63|
|[[:results:exp407|Thapsigargin 0.005μM R07 exp407]]|3.63|
|[[:results:exp416|Tubacin 1.6μM R07 exp416]]|3.8|
|[[:results:exp400|Senexin-A 25μM R07 exp400]]|4.05|
|[[:results:exp466|Cannabidiol 20μM R08 exp466]]|4.5|
</modal>

<modal id='Most_Correlated_Genes' size='lg' title='Most Correlated Genes in Chemogenomics'>
^Gene^Correlation^
|[[:human genes:p:pten|PTEN]]|0.404|
</modal>

<modal id='Essential_Avana' size='lg' title='Tissues where Essential in the Avana Dataset (DepMap 20Q1)'>
Global Fraction of Cell Lines Where Essential: 7/726
^Tissue^Fraction Of Cell Lines Where Essential^
|1290807.0|0/1|
|909776.0|0/1|
|bile duct|0/28|
|blood|7/28|
|bone|0/25|
|breast|0/33|
|central nervous system|0/56|
|cervix|0/4|
|colorectal|0/17|
|esophagus|0/13|
|fibroblast|0/1|
|gastric|0/15|
|kidney|0/21|
|liver|0/20|
|lung|0/75|
|lymphocyte|0/14|
|ovary|0/26|
|pancreas|0/24|
|peripheral nervous system|0/16|
|plasma cell|0/15|
|prostate|0/1|
|skin|0/24|
|soft tissue|0/7|
|thyroid|0/2|
|upper aerodigestive|0/22|
|urinary tract|0/29|
|uterus|0/5|
</modal>

== Essentiality in NALM6  ==
    * **<color #00a2e8>Essentiality Rank</color>**: 2301
    * **<color #00a2e8>Expression level (log2 read counts)</color>**: 4.55 
<button type='primary' size='small' modal='Dist_expr'>Expression Distribution</button>
<modal id='Dist_expr' size='lg' title='SPI1 Expression in NALM6 Cells: 4.55'>
{{:chemogenomics:nalm6 dist.png?nolink |}}
</modal>